Morgan Stanley Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock

Key Points

• Morgan Stanley raised its target on Neurocrine to $191 (from $185) while maintaining an "equal weight" rating, implying about a 31.23% upside from the prior close.
• Several firms have lifted price targets this week (including Piper Sandler, Canaccord, HC Wainwright and RBC), leaving a MarketBeat consensus of Moderate Buy with a $183 price target and most analysts rated the stock as Buy (1 Strong Buy, 16 Buy, 5 Hold).
• Fundamental catalysts driving investor interest include a Q1 beat with revenue up ~44% YoY and management reaffirming 2026 Ingrezza net sales guidance of $2.7–$2.8B, plus the announced acquisition of Soleno Therapeutics (adds VYKAT XR and pipeline diversification).

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its target price boosted by equities researchers at Morgan Stanley from $185.00 to $191.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Morgan Stanley's target price would suggest a potential upside of 31.23% from the company's previous close.

NBIX has been the subject of several other research reports. BMO Capital Markets dropped their target price on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a "market perform" rating for the company in a research report on Thursday, February 12th. Royal Bank Of Canada lifted their price target on Neurocrine Biosciences from $176.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday. Canaccord Genuity Group boosted their price objective on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a "buy" rating in a report on Tuesday, April 7th. HC Wainwright increased their target price on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a "buy" rating in a report on Tuesday, April 7th. Finally, Zacks Research upgraded Neurocrine Biosciences from a "strong sell" rating to a "hold" rating in a research report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $183.00.

Neurocrine Biosciences Price Performance

NBIX traded up $10.48 during trading hours on Wednesday, reaching $145.54. 1,384,709 shares of the stock traded hands, compared to its average volume of 1,151,320. Neurocrine Biosciences has a fifty-two week low of $115.66 and a fifty-two week high of $160.18. The company has a market cap of $14.64 billion, a price-to-earnings ratio of 31.23, a PEG ratio of 0.67 and a beta of 0.34. The firm's fifty day simple moving average is $130.37 and its two-hundred day simple moving average is $137.72.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts' consensus estimates of $2.36 by ($0.48). The firm had revenue of $805.50 million during the quarter, compared to analysts' expectations of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business's quarterly revenue was up 28.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.69 earnings per share. On average, research analysts predict that Neurocrine Biosciences will post 6.57 earnings per share for the current year.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. USA Financial Formulas bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth approximately $25,000. Golden State Wealth Management LLC increased its position in Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company's stock worth $26,000 after buying an additional 100 shares during the period. Eastern Bank bought a new stake in Neurocrine Biosciences in the third quarter valued at $27,000. DJE Kapital AG bought a new stake in Neurocrine Biosciences in the fourth quarter valued at $28,000. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock valued at $25,000 after acquiring an additional 135 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Q1 results beat expectations: revenue of $811.0M (up ~44% YoY), EPS ahead of estimates, INGREZZA sales described as a key driver, and management reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8B — a core reason investors are buying the stock. Neurocrine Q1 2026 Financial Results
• Positive Sentiment: Acquisition announced: Neurocrine agreed to acquire Soleno Therapeutics (includes VYKAT XR for hyperphagia in Prader‑Willi), expanding commercial footprint and pipeline — adds potential new revenue stream and diversification. Acquisition Announcement
• Positive Sentiment: Multiple bullish analyst moves: Piper Sandler raised its PT to $207 (overweight), RBC raised its PT to $180 (outperform), Wedbush to $176 (outperform), and Guggenheim reaffirmed a $175 buy — collectively pushing consensus upside and supporting today’s rally. Analyst Price Target Raises
• Positive Sentiment: Peer‑reviewed guidance for CRENESSITY adoption published: expert recommendations in The Journal of Clinical Endocrinology & Metabolism give clinicians practical algorithms to reduce glucocorticoid dosing after starting CRENESSITY, which should help real‑world uptake and positioning in CAH. CRENESSITY Publication
• Neutral Sentiment: Investor outreach: management will present at the Bank of America Health Care Conference (May 12), offering more visibility on execution and the 2027 outlook — a near‑term event investors will watch. BofA Conference Notice
• Neutral Sentiment: Earnings materials/transcript available: slide deck and call transcripts provide detail on drivers (INGREZZA, CRENESSITY launch, pipeline moves) for investors who want to dig into unit economics and margin trajectory. Q1 Slide Deck
• Negative Sentiment: Some market commentary questions valuation/positioning after recent gains — a Yahoo piece asks whether the stock is pricing in too much caution, signaling there are analysts/commentators worried about upside already being in the price. Yahoo Valuation Piece

About Neurocrine Biosciences

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.